Targets › THRA
12 programs from 12 companies in 15 trials: 6 Phase 2, 4 Phase 4, 3 Phase 3, 2 Phase 1; Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.
[Isoform Alpha-1]: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine..; FUNCTION: [Isoform Alpha-2]: Does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action. (UniProt, P10827)
Open in Phaseline: the race on THRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Elyes Kamoun | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 4 | Hypothyroidism Primary | Dec 2026 |
| University of Pennsylvania | Levothyroxine Sodium Thyroid hormone receptor agonist | THRA, THRB | Phase 4 | Hypothyroidism | Apr 2028 |
| Daihong Liu | Anti-Thymocyte Globulin (ATG) (Thymoglobulin) Anti-thymocyte immunoglobulin; depletes T cells through immune recognition | THRA, THRB | Phase 4 | Hematopoietic Stem Cell Transplantation | Aug 2028 |
| Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 3 | Obesity | Nov 2026 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 3 | Hypothyroidism; Irradiation | Sep 2029 |
| Rare Thyroid Therapeutics International | Tiratricol Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Allan-Herndon-Dudley Syndrome | Jul 2027 |
| AbbVie | Armour Thyroid Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3) | THRA, THRB | Phase 2 | Hypothyroidism | Sep 2027 |
| SAb Biotherapeutics | SAB-142 Human anti-thymocyte immunoglobulin | THRA | Phase 2 | Type 1 Diabetes | Nov 2027 |
| UConn Health | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Hypothyroidism | Dec 2027 |
| VA Office of Research and Development | Levothyroxine Sodium Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Nonalcoholic Steatohepatitis | Dec 2029 |
| Jeffrey Veale, MD | rabbit anti-thymocyte globulin (rATG) Polyclonal immunoglobulin that depletes T cells by binding to thymocyte antigens | THRA | Phase 1 | Renal Transplant Rejection | May 2027 |
| Stephan Busque | rabbit Anti-Thymocyte Globulin (rATG) Polyclonal antibody targeting T cells to deplete recipient lymphocytes | THRA | Phase 1 | Immune Tolerance | Oct 2028 |
Hypothyroidism (4) Hematopoietic Stem Cell Transplantation (3) Renal Transplant Rejection (1) Hypothyroidism; Irradiation (1) Hypothyroidism Primary (1) Obesity (1) Allan-Herndon-Dudley Syndrome (1) Immune Tolerance (1) Type 1 Diabetes (1) Nonalcoholic Steatohepatitis (1)
small molecule (9), other (2), protein or peptide (1)
Daihong Liu (1) Jeffrey Veale, MD (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Elyes Kamoun (1) Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) Rare Thyroid Therapeutics International (1) Stephan Busque (1) AbbVie (1) SAb Biotherapeutics (1) University of Pennsylvania (1) UConn Health (1) VA Office of Research and Development (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.